Posts by: Alice Melão

An investigative drug developed by Kadmon called KD025 was shown to be safe and effective to prevent lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to Phase 2 trial ... Read more

February 14, 2018February 14, 2018

FDA Approves Vertex’s Symdeko to Treat CF Patients 12 and Older

Cystic Fibrosis

The U.S. Food and Drug Administration (FDA) has approved the third targeted therapy developed by Vertex Pharmaceuticals for patients with cystic fibrosis (CF). Symdeko can now be used in the United ... Read more

January 24, 2018January 24, 2018

Finalists for $1 million IPF Catalyst Challenge Includes patientMpower

Idiopathic Pulmonary Fibrosis, News

PatientMpower is one of the selected finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). The IPF Catalyst Challenge, being held ... Read more

January 17, 2018January 17, 2018

Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Reports of liver injuries stemming from the pulmonary fibrosis therapy Ofev (nintedanib), including a fatality, have prompted Health Canada to issue a safety warning about it to medical professionals. The regulatory agency said ... Read more

January 4, 2018January 4, 2018

FoxO3 Protein Found to Be Key Regulator of Fibrosis in Lungs, Study Finds

Idiopathic Pulmonary Fibrosis, News

The protein FoxO3, which regulates the levels of other proteins in cells, was found to play a key role in the development of pulmonary fibrosis, researchers reported. Results of the ... Read more

December 20, 2017December 20, 2017

Aggressive Treatment of IPF Patients with Lung Cancer Rarely Best Option, Experts Say

Idiopathic Pulmonary Fibrosis, Lung Cancer, News

A group of clinician-reseachers with expertise in lung diseases suggest in a commentary that people with both idiopathic pulmonary fibrosis (IPF) and lung cancer are best managed with a goal of “first, do ... Read more

December 12, 2017December 12, 2017

Kalydeco Seen As Safe in Treating CF in Young Children, Ages 1 to 2, Study Data Show

Cystic Fibrosis, News

Kalydeco (ivacaftor) was shown to be safe and well-tolerated in 1- and 2-year-old children with cystic fibrosis (CF), based on data from a Phase 3 trial, Vertex Pharmaceuticals announced. Additionally, trial ... Read more

December 5, 2017December 5, 2017

Veracyte Says Study Backs Up Usefulness of Envisia Genomic Classifier as IPF Diagnostic Tool

Idiopathic Pulmonary Fibrosis, News

Veracyte says new data confirming the analytical validity of its Envisia Genomic Classifier demonstrate its benefits in diagnosing idiopathic pulmonary fibrosis (IPF). The study, “Analytical performance of Envisia: a genomic classifier for ... Read more

November 21, 2017November 21, 2017

Many European IPF Patients Are Not Receiving Anti-lung-scarring Therapies, Survey Indicates

Idiopathic Pulmonary Fibrosis, News

Despite anti-fibrotic therapies’ ability to help idiopathic pulmonary fibrosis patients, more than half of Europeans who have the disease are not receiving them. That’s because a lot fo physicians are ... Read more

November 3, 2017November 3, 2017

Real-World Study Confirms Benefits of Percepta Genomic Classifier in Diagnosing Lung Cancer

Lung Cancer, News

Real-world clinical data has shown that the Percepta Bronchial Genomic Classifier can help identify patients with a low risk of lung cancer, significantly reducing the need for invasive, risky, and expensive ... Read more